Home
Products & Services
Support
About
Contact Us
FinancialContent is the trusted provider of stock market information to the media industry.
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Axovant Sciences Ltd (NQ: AXON)
1.220 USD  UNCHANGED
Last Price  /  Updated: 6:35 PM EST, Feb 13, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 0
Open 1.220
Bid (Size) 1.230 (4)
Ask (Size) 1.240 (14)
Prev. Close 1.220
Today's Range 1.220 - 1.220
52wk Range 0.9300 - 3.870
Shares Outstanding 107,788,074
Dividend Yield N/A
Performance
YTD
+11.93%
+11.93%
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
+6.09%
+6.09%
1 Year
-64.33%
-64.33%
Top News
More News
Axovant Announces Formation of Arvelle Therapeutics and Strategic Transition of Legacy Small Molecule Team Into Newly Formed Company
Axovant Sciences (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announces the formation of Arvelle Therapeutics and the strategic transition of its legacy small... Read More
from GlobeNewswire News Releases
Axovant Announces Third Fiscal Quarter 2018 Financial Results and Corporate Updates
Axovant Sciences (NASDAQ: AXON), a clinical-stage company developing innovative gene therapies, today provided financial results and corporate updates for its third fiscal quarter and nine months ended... Read More
from GlobeNewswire News Releases
More News
Read More
Axovant Announces Presentation at J.P. Morgan Healthcare Conference and Anticipated 2019 Clinical Development Milestones
from GlobeNewswire News Releases
Roivant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference
from PR Newswire
Detailed Research: Economic Perspectives on Canopy Growth, ArQule, MoneyGram International, Teradata, Clovis Oncology, and Axovant Sciences — What Drives Growth in Today's Competitive Landscape
from GlobeNewswire News Releases
Hercules Capital Announces Multiple Outstanding Achievements by Numerous Investment Portfolio Companies
from Business Wire News Releases
Roivant Sciences and Daiichi Sankyo Enter into Broad Pipeline Partnership
from PR Newswire
Axovant Sciences Announces Pricing of $30 Million Public Offering of Common Shares
from GlobeNewswire News Releases
Axovant Sciences Announces Public Offering of Common Shares
from GlobeNewswire News Releases
Axovant Licenses Investigational Gene Therapies for GM1 Gangliosidosis, Tay-Sachs and Sandhoff Diseases from University of Massachusetts Medical School
from GlobeNewswire News Releases
Here's Why Axovant Gene Therapies Rocketed Higher Today
category Market News , AXON
from Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
   
© Copyright FinancialContent Services, Inc.